ES2177642T3 - Uso de ciertos derivados de acido metanobisfosfonico para prevenir el desprendimiento y la migracion de protesis. - Google Patents

Uso de ciertos derivados de acido metanobisfosfonico para prevenir el desprendimiento y la migracion de protesis.

Info

Publication number
ES2177642T3
ES2177642T3 ES95914495T ES95914495T ES2177642T3 ES 2177642 T3 ES2177642 T3 ES 2177642T3 ES 95914495 T ES95914495 T ES 95914495T ES 95914495 T ES95914495 T ES 95914495T ES 2177642 T3 ES2177642 T3 ES 2177642T3
Authority
ES
Spain
Prior art keywords
migration
pct
methanophyphosphonic
protesis
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95914495T
Other languages
English (en)
Inventor
Allen E Goodship
John Kenwright
Jonathan Green
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2177642T3 publication Critical patent/ES2177642T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Dental Preparations (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

INVENCION QUE SE REFIERE A CIERTOS DERIVADOS DE ACIDO METANOBISFOSFONICO (PARA LA FABRICACION DE UN COMPUESTO FARMACEUTICO) QUE PERMITEN PREVENIR Y TRATAR LA PERDIDA Y MIGRACION PROTESICA EN LOS MAMIFEROS INCLUIDO EL HOMBRE.
ES95914495T 1994-05-04 1995-04-24 Uso de ciertos derivados de acido metanobisfosfonico para prevenir el desprendimiento y la migracion de protesis. Expired - Lifetime ES2177642T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9408775A GB9408775D0 (en) 1994-05-04 1994-05-04 Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration

Publications (1)

Publication Number Publication Date
ES2177642T3 true ES2177642T3 (es) 2002-12-16

Family

ID=10754497

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95914495T Expired - Lifetime ES2177642T3 (es) 1994-05-04 1995-04-24 Uso de ciertos derivados de acido metanobisfosfonico para prevenir el desprendimiento y la migracion de protesis.

Country Status (18)

Country Link
US (1) US5965547A (es)
EP (1) EP0758241B1 (es)
JP (1) JPH09512816A (es)
AT (1) ATE218350T1 (es)
AU (1) AU693541B2 (es)
DE (1) DE69526937T2 (es)
DK (1) DK0758241T3 (es)
ES (1) ES2177642T3 (es)
FI (1) FI118590B (es)
GB (1) GB9408775D0 (es)
HU (1) HUT74984A (es)
IL (1) IL113566A (es)
NO (1) NO310057B1 (es)
NZ (1) NZ283430A (es)
PT (1) PT758241E (es)
TW (1) TW458779B (es)
WO (1) WO1995030421A1 (es)
ZA (1) ZA953537B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
US6117856A (en) * 1996-02-14 2000-09-12 Binderman; Itzhak Topical bisphosphonates for prevention of bone resorption
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
GB2336311A (en) * 1998-04-15 1999-10-20 Merck & Co Inc Bisphosphonate Dosing Regimen
US6137012A (en) 1998-10-13 2000-10-24 E. I. Du Pont De Nemours And Company Phosphole and diphosphole ligands for catalysis
ATE303153T1 (de) * 1998-12-04 2005-09-15 Roche Diagnostics Gmbh Ibandroinsäure zur förderung der osseointegration der endoprothesen
JP2002536123A (ja) * 1999-02-09 2002-10-29 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 抗吸収性骨セメントならびに同種、自家、および異種骨移植片
EP1118328A1 (en) * 1999-08-02 2001-07-25 Toray Industries, Inc. Insertion stabilizers for implants
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
SI1591122T1 (sl) 2000-06-20 2013-02-28 Novartis Ag Postopek za aplikacijo bisfosfonatov
DE60113537T3 (de) * 2000-06-20 2013-05-29 Novartis Ag Methode zur verabreichung von biphosphonaten
AU2001287260A1 (en) * 2000-07-12 2002-01-21 Ecole Polytechnique Federale De Lausanne (Epfl) Active biocoating for bone implant
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
EP1880744B1 (en) * 2002-05-10 2015-01-21 F.Hoffmann-La Roche Ag Bisphosphonic acids for the treatment and prevention of osteoporosis
AU2003270196A1 (en) * 2002-09-16 2004-04-30 Kenneth W. Lyles Method for preventing or reducing secondary fractures after hip fracture
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
WO2008059060A1 (en) * 2006-11-17 2008-05-22 Besins Healthcare Liquid pharmaceutical compositions comprising a bisphosphonate compound
EP1958649A1 (en) * 2007-02-14 2008-08-20 Graftys Injectable calcium-phosphate cement releasing a bone resorption inhibitor
EP2136814A4 (en) * 2007-03-21 2012-05-30 Univ Duke MEDICAL KITS AND FORMULATIONS FOR PREVENTING, TREATING OR REDUCING SECONDARY FRACTURES FROM A PREVIOUS FRACTURE
WO2008152518A2 (en) * 2007-05-16 2008-12-18 Actavis Group Ptc Ehf Process for the preparation of risedronic acid or risedronate sodium
CN102639137A (zh) 2009-09-01 2012-08-15 杜克大学 双膦酸类组合物及其治疗心力衰竭的方法
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
EP2780021A4 (en) 2011-11-16 2015-08-05 Univ Duke BISPHOSPHONATE COMPOSITIONS AND METHODS FOR TREATING AND / OR REDUCING HEART FAILURE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
EP0275821B1 (de) * 1986-11-21 1992-02-26 Ciba-Geigy Ag Neue substituierte Alkandiphosphonsäuren
JPH05163150A (ja) * 1991-05-13 1993-06-29 E R Squibb & Sons Inc アテローム性動脈硬化症の抑制・治療剤
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices

Also Published As

Publication number Publication date
DK0758241T3 (da) 2002-09-23
WO1995030421A1 (en) 1995-11-16
HUT74984A (en) 1997-03-28
ATE218350T1 (de) 2002-06-15
HU9603042D0 (en) 1997-01-28
ZA953537B (en) 1995-11-06
DE69526937T2 (de) 2003-01-02
NO964486D0 (no) 1996-10-22
EP0758241A1 (en) 1997-02-19
NO964486L (no) 1996-10-22
FI964332A (fi) 1996-10-28
TW458779B (en) 2001-10-11
IL113566A0 (en) 1995-08-31
AU2146695A (en) 1995-11-29
JPH09512816A (ja) 1997-12-22
PT758241E (pt) 2002-10-31
US5965547A (en) 1999-10-12
IL113566A (en) 2002-05-23
NO310057B1 (no) 2001-05-14
AU693541B2 (en) 1998-07-02
DE69526937D1 (de) 2002-07-11
NZ283430A (en) 2000-06-23
GB9408775D0 (en) 1994-06-22
FI964332A0 (fi) 1996-10-28
FI118590B (fi) 2008-01-15
EP0758241B1 (en) 2002-06-05

Similar Documents

Publication Publication Date Title
ES2177642T3 (es) Uso de ciertos derivados de acido metanobisfosfonico para prevenir el desprendimiento y la migracion de protesis.
NO307027B1 (no) Anvendelse av riluzol ved behandling av neurologiske lesjoner relatert til traumatiske skader
DE69326776T2 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
ATE226436T1 (de) Neue verwendung von dexmedetomidin
FI972434A (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
DK0722325T3 (da) Præparat til behandling eller forebyggelse af herpes
IL108283A0 (en) Use of riluzole for promoting restoration following radiation
IL107917A0 (en) Triazoloquinazolines, their preparation and their use as medicaments
MX9605327A (es) Uso de ciertos derivados de acido metanbisfosfonico para prevenir el aflojamiento de las protesis y la emigracion de las protesis.
CA2183764A1 (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration